Hinova Received $40 Million In Series B Financing

According to China Venture, Hinova just received 40 million dollars in Series B financing. This round of financing was led by Hermed Capital and Fosun Pharmaceutical and followed by Lang Sheng Investment, Prosper Capital and few other organizations. The funds will be used for the R&D of phase 3 clinical use of the new prostate cancer drug HC-1119, and the development of a few other drugs.

Hinova was founded in 2013, the company mainly focuses on the R&D of new drugs. The company relies on leading generations, PROTAC, prostate cancer treatment and other technologies to develop new drug varieties with market potential. At present, there are several new drugs including prostate cancer, breast tumor, gout and other diseases in the clinical and preclinical research stage. The company has applied for nearly 100 PCT and Chinese invention patents.

Hermed Capital is a Hong Kong-based financial services company that offers related advisory services.

Fosun Pharma is a leading pharmaceutical company in China.

Lang Sheng Investment is a leading life science and big data investment firm in China committed to helping exceptional entrepreneurs build the next generation of great healthcare and big data companies.

Founded in 2016, Prosper Capital is an asset management company in China.